Clinical Trial Update: Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients [Phase 3]

View source ↗

Summary

The Phase 3 long-term safety study of KW-6002 (Istradefylline) in Parkinson's disease has completed. The update confirms completion status of this safety study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• istradefylline (istradefylline)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED